NICE limits access to cancer drugs, study confirms

pharmafile | November 10, 2010 | News story | Sales and Marketing |ย ย BMS, Bristol-Myers Squibb, Cancer, Cancer Drugs Fund, IPSOR, Maximilian Lebmeier, NICE, htaย 

NICE became more restrictive in its assessment of new cancer drugs between 2007 and 2009, a new report suggests.

The review, conducted by Bristol-Myers Squibb, produced its analysis from a list of NICE guidance published between 2007 to the end of 2009 using a health technology resource website.

The research showed that in 2007 one in three new drugs was fully recommended for all eligible patients, but that this dropped to just one in 10 by the end of 2009.

BMSโ€™ associate director health economics Maximilian Lebmeier, who led the analysis, said: โ€œThe coalition government has stated their commitment to widening access to medicines and we fully support this. 

Advertisement

โ€œThe Cancer Drugs Fund is a good interim initiative for cancer patients, but we would like to see wider reform of the HTA system to make it fairer for all patients and widen access to effective medicines.โ€

Ben Adams

Related Content

Combination treatments: Takedaโ€™s Implementation Framework and the broader landscape

Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …

nerve-cell-2213009_960_720

Central nervous system cancer metastases โ€“ the evolution of diagnostics and treatment

The current forms of immunotherapy, how T cell therapy works and what the future holds

BioMed X and Servier launch Europeโ€™s first XSeed Labs to advance AI-powered antibody design

BioMed X and Servier have announced the launch of Europeโ€™s first XSeed Labs research project, …

The Gateway to Local Adoption Series

Latest content